Compare VTIX & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTIX | MDWD |
|---|---|---|
| Founded | 2013 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 222.0M | 193.3M |
| IPO Year | N/A | 2013 |
| Metric | VTIX | MDWD |
|---|---|---|
| Price | $5.92 | $16.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $36.00 |
| AVG Volume (30 Days) | ★ 195.7K | 89.7K |
| Earning Date | 08-11-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $48.88 |
| Revenue Next Year | N/A | $35.08 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.39 | $14.90 |
| 52 Week High | $9.00 | $22.51 |
| Indicator | VTIX | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 40.49 | 50.53 |
| Support Level | $5.78 | $16.77 |
| Resistance Level | $9.00 | $18.71 |
| Average True Range (ATR) | 0.95 | 0.85 |
| MACD | -0.24 | 0.06 |
| Stochastic Oscillator | 7.76 | 67.74 |
Virtuix Holdings Inc develops technologies for immersive virtual environments, including both simulated and real-world applications. It develops virtual reality hardware and software, including the Omni Pro, an omni-directional treadmill designed to allow users to walk and run in multiple directions inside video games and other virtual worlds. The company operates at the intersection of gaming, fitness, and enterprise virtual reality. It has commercialized three products. The company operates in a single operating segment: the design, development, marketing, and sale of omni-directional treadmills, accessories, and related services to consumer and commercial customers. It derives revenue through a combination of hardware sales and recurring software and service income.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.